QualityStocks would like to highlight Aeolus Pharmaceuticals Inc. (OTCBB: AOLS). The company is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a patented, small molecule catalytic antioxidant that mimics and thereby amplifies the body’s natural enzymatic systems for eliminating reactive oxygen species, or free radicals. Studies funded by the National Institutes for Health are currently underway evaluating AEOL 10150 as a treatment for exposure to mustard gas and will shortly be initiated to evaluate the compound as a treatment for exposure to chlorine gas.
In the company’s news Friday,
Aeolus Pharmaceuticals announced that it has generated a net loss of $459,000, or $0.01 per basic share, for the three months ended December 31, 2008. This compares to a loss of $641,000, or $0.02 per basic share, for the three months ended December 31, 2007, a decrease of 28%.
John L. McManus, President and CEO, stated, “Results for the quarter continue to demonstrate our success in reducing overhead and successfully partnering with universities and the government to further the development of AEOL 10150. While making wise use of our cash is important, it is also critical that we move forward the development of our lead drug candidate AEOL10150.”
“During the past quarter we initiated a study of AEOL 10150 as a countermeasure against exposure to radiation at Duke University. We expect to have some of the results of that study before the end of the current quarter. Additionally, we expect to begin studies of AEOL 10150 as a treatment for mustard gas and chlorine gas this quarter,” he added.
According to the press release, R&D expenses were lower in the first quarter of fiscal year 2009 compared to last year as a result of a decline in grant expenses. General and administrative expenses also decreased as a result of a decline in stock based compensation expense and Board of Directors expense. At the end of the quarter, Aeolus had $169,000 in cash and cash equivalents and 32,030,874 common shares outstanding.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
